drugset / Trial / NCT01313936
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
Phase 1
Completed
32 enrolled
University of California, San Francisco
Thrasher Research Fund · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a pilot study to determine whether doses of 15 mCi/kg and 18 mCi/kg of 131I-MIBG are tolerable when given with irinotecan/vincristine on a one week schedule to children and young adults with high-risk refractory/relapsed neuroblastoma.
Timeline
- Start
- 2011-03
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metaiodobenzylguanidine | Diagnostic / imaging agent | 15 mbq/kg | — |
| Subject | Metaiodobenzylguanidine | Diagnostic / imaging agent | 18 mbq/kg | — |